HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 635,100 shares, a growth of 7.6% from the August 15th total of 590,200 shares. Approximately 4.8% of the company’s shares are short sold. Based on an average trading volume of 71,900 shares, the short-interest ratio is currently 8.8 days.
HilleVax Stock Down 4.2 %
NASDAQ HLVX traded down $0.61 on Tuesday, reaching $14.07. The stock had a trading volume of 2,196 shares, compared to its average volume of 63,195. The company has a quick ratio of 13.80, a current ratio of 13.80 and a debt-to-equity ratio of 0.11. HilleVax has a 12-month low of $11.35 and a 12-month high of $23.10. The stock has a fifty day moving average price of $13.94 and a two-hundred day moving average price of $15.05.
HilleVax (NASDAQ:HLVX – Get Free Report) last announced its earnings results on Monday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.11. On average, equities research analysts predict that HilleVax will post -3.3 earnings per share for the current year.
Institutional Trading of HilleVax
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
- Five stocks we like better than HilleVax
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Where to Find Earnings Call Transcripts
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- What is the Dogs of the Dow Strategy? Overview and Examples
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.